Mumbai : Alkem Laboratories Ltd. (BSE: 539523, NSE: ALKEM, “Alkem”
and its subsidiaries) today announced the launch of semaglutide in single-shot pre-filled
syringes in multiple dose strengths at price starting INR350.
Alkem is the first company in India to introduce semaglutide in single-shot pre-filled syringe
format, expanding treatment options for patients and lowering entry barriers with its
affordable pricing. The ready-to-use single shot pre-filled syringe format offers enhanced
access, and convenience.
The company has received approval from the Drugs Controller General of India (DCGI) to
manufacture and market semaglutide pre-filled syringes for the management of Type 2
diabetes mellitus and obesity as an adjunct to diet and exercise.
In March 2026, Alkem had already launched semaglutide in pre-filled disposable and reusable
injection pens format in the Indian market. The company has also received regulatory
approval for semaglutide vials, which will be launched soon.
Commenting on the development, Dr. Vikas Gupta, Chief Executive Officer, Alkem said,
“Semaglutide has the potential to change how we manage metabolic disorders. With the
launch of our pre-filled syringes, we are widening the choice available to doctors and
patients, alongside the pen options we have already introduced. In India, where we are seeing
a continuous rise in disease burden, offering multiple, practical drug delivery formats is an
important step in helping more patients start and stay on the therapy.”
Alkem remains committed to advancing high-quality, affordable medicines across key
therapeutic areas and supporting better patient care in India.
